Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Foundayo

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Foundayo

9 stories · every one Fact-Checked
Lilly_OFG_Bottle_Tablet_G1_BottleOnly_v03Health TidingsLilly Expands Zepbound and Foundayo Access Through Hims & HersEli Lilly has partnered with Hims & Hers Health to expand access to its FDA-approved obesity medicines, Zepbound and Foundayo, through the telehealth platform.6 Nov 2026 · 3 min read
Fact-Checked
Lilly_OFG_Bottle_Tablet_G1_BottleOnly_v03Clinical TrialsLilly’s Oral GLP-1 Foundayo Shows Clear Edge Over Oral SemaglutideNew Phase 3 ACHIEVE data showed that Lilly’s oral GLP-1 receptor agonist Foundayo (orforglipron) delivered greater reductions in HbA1c and body weight than oral semaglutide, while also outperforming…9 Jun 2026 · 3 min read
Fact-Checked
Lilly_OFG_Bottle_Tablet_G1_BottleOnly_v03Health TidingsFoundayo Shows Consistent Weight Loss Across Menopause Stages in Phase 3 ATTAIN StudiesPost‑hoc analyses from Lilly’s Phase 3 ATTAIN program show that Foundayo, a once‑daily oral GLP‑1 receptor agonist, produced clinically meaningful weight loss and waist circumference reductions in women…8 Jun 2026 · 3 min read
Fact-Checked
Lilly_OFG_Bottle_Tablet_G1_BottleOnly_v03Clinical TrialsEli Lilly’s Foundayo Shows Up to 13% Weight Loss in Older Adults in ATTAIN TrialsEli Lilly reported new Phase 3 data at ECO 2026 demonstrating that older adults treated with Foundayo (orforglipron) achieved clinically meaningful weight loss across the ATTAIN‑1 and ATTAIN‑2…23 May 2026 · 3 min read
Fact-Checked
Lilly_OFG_Bottle_Tablet_G1_BottleOnly_v03Clinical TrialsLilly Reports Long-Term Weight Maintenance Data for Foundayo and Zepbound at ECO 2026New Phase 3b data from Lilly showed that patients with obesity maintained most prior weight loss with either continued Zepbound therapy or a switch to oral Foundayo after…13 May 2026 · 2 min read
Fact-Checked
FOUN_TM_OnDly_Tblt_6dose_RGB_FC_Pos_ALMDrugs Safety AlertFDA Requires Extensive Postmarketing Safety Data for FoundayoFDA approval of Foundayo (orforglipron) includes mandated pediatric studies, pregnancy registries, and long-term surveillance for medullary thyroid carcinoma, cardiovascular events, and liver safety risks.16 Apr 2026 · 3 min read
Fact-Checked
31161Health TidingsLilly Expands Obesity Portfolio With Foundayo Market LaunchEli Lilly and Company has launched Foundayo (orforglipron) in the U.S. for chronic weight management following FDA approval.9 Apr 2026 · 3 min read
Fact-Checked
9249Clinical TrialsNovo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and Foundayo in FocusNovo Nordisk has released ORION study results shortly after Foundayo’s FDA approval, reporting superior weight loss and lower discontinuation rates with oral semaglutide versus orforglipron in an indirect…2 Apr 2026 · 3 min read
Fact-Checked
towfiqu-barbhuiya-hn2hQoALBCk-unsplash (1)New Drug ApprovalLilly Brings Weight-Loss Pill to Market with Foundayo FDA ApprovalFDA approves Lilly’s once-daily oral GLP-1 Foundayo for obesity, showing strong Phase 3 weight loss and positioning it as a key rival in the emerging Wegovy pill segment.1 Apr 2026 · 3 min read
Fact-Checked
Page 1 of 1